QEt’s proposed €5 billion cross-sector growth fund is positioned to address European biotech’s funding shortfall by creating another homegrown route for growth capital. The initiative is framed around widening access to follow-on financing as investors and companies navigate a narrower biotech capital base. For executives, the signal is about deal continuity: growth-stage biotechs often stall when the “capital gap” widens between early seed and late-stage assets. If implemented at scale, the fund could provide more predictable capacity for platform and clinical expansion programs across European sponsors.